CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,590 | +12.1% | 718 | +38.6% | 0.02% | +14.3% |
| Q2 2023 | $29,081 | +24.1% | 518 | 0.0% | 0.01% | +16.7% |
| Q1 2023 | $23,429 | +11.3% | 518 | 0.0% | 0.01% | 0.0% |
| Q4 2022 | $21,057 | -38.1% | 518 | 0.0% | 0.01% | -40.0% |
| Q3 2022 | $34,000 | +9.7% | 518 | +0.4% | 0.02% | +5.3% |
| Q2 2022 | $31,000 | -42.6% | 516 | -39.5% | 0.02% | -29.6% |
| Q1 2022 | $54,000 | +25.6% | 853 | +51.0% | 0.03% | +35.0% |
| Q4 2021 | $43,000 | +34.4% | 565 | +97.6% | 0.02% | 0.0% |
| Q3 2021 | $32,000 | -15.8% | 286 | +21.7% | 0.02% | -13.0% |
| Q2 2021 | $38,000 | +31.0% | 235 | 0.0% | 0.02% | +9.5% |
| Q1 2021 | $29,000 | -86.3% | 235 | -83.0% | 0.02% | -88.0% |
| Q4 2020 | $212,000 | +53.6% | 1,385 | -15.8% | 0.18% | +28.7% |
| Q3 2020 | $138,000 | – | 1,644 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |